Myozap Deficiency Promotes Adverse Cardiac Remodeling via Differential Regulation of Mitogen-activated Protein Kinase/Serum-response Factor and β-Catenin/GSK-3β Protein Signaling*

Background: Little is known about cardiac function of myozap, a novel intercalated disc (ID) protein. Results: Myozap deficiency leads to the junctional remodeling, cardiomyopathy, heart failure, and increased mortality in response to increased biomechanical stress. Conclusion: Myozap is required for proper adaptation to increased biomechanical stress. Significance: We provide an essential role of the ID in general and myozap in particular in the context of cardiac remodeling. The intercalated disc (ID) is a “hot spot” for heart disease, as several ID proteins have been found mutated in cardiomyopathy. Myozap is a recent addition to the list of ID proteins and has been implicated in serum-response factor signaling. To elucidate the cardiac consequences of targeted deletion of myozap in vivo, we generated myozap-null mutant (Mzp−/−) mice. Although Mzp−/− mice did not exhibit a baseline phenotype, increased biomechanical stress due to pressure overload led to accelerated cardiac hypertrophy, accompanied by “super”-induction of fetal genes, including natriuretic peptides A and B (Nppa/Nppb). Moreover, Mzp−/− mice manifested a severe reduction of contractile function, signs of heart failure, and increased mortality. Expression of other ID proteins like N-cadherin, desmoplakin, connexin-43, and ZO-1 was significantly perturbed upon pressure overload, underscored by disorganization of the IDs in Mzp−/− mice. Exploration of the molecular causes of enhanced cardiac hypertrophy revealed significant activation of β-catenin/GSK-3β signaling, whereas MAPK and MKL1/serum-response factor pathways were inhibited. In summary, myozap is required for proper adaptation to increased biomechanical stress. In broader terms, our data imply an essential function of the ID in cardiac remodeling beyond a mere structural role and emphasize the need for a better understanding of this molecular structure in the context of heart disease.

[1]  M. Poteser,et al.  Targeting cardiac hypertrophy: toward a causal heart failure therapy. , 2014, Journal of cardiovascular pharmacology.

[2]  Arjun Deb.  Cell-cell interaction in the heart via Wnt/β-catenin pathway after cardiac injury. , 2014, Cardiovascular research.

[3]  N. Frey,et al.  Dysbindin is a potent inducer of RhoA–SRF-mediated cardiomyocyte hypertrophy , 2013, The Journal of cell biology.

[4]  N. Frey,et al.  Mice with cardiac-restricted overexpression of Myozap are sensitized to biomechanical stress and develop a protein-aggregate-associated cardiomyopathy. , 2013, Journal of molecular and cellular cardiology.

[5]  Joseph A. Hill,et al.  Pathological Ventricular Remodeling: Mechanisms Part 1 of 2 , 2013, Circulation.

[6]  S. Rizzo,et al.  Intercalated disc abnormalities, reduced Na(+) current density, and conduction slowing in desmoglein-2 mutant mice prior to cardiomyopathic changes. , 2012, Cardiovascular research.

[7]  H. Katus,et al.  Cardiac remodeling is not modulated by overexpression of muscle LIM protein (MLP) , 2012, Basic Research in Cardiology.

[8]  F. van Roy,et al.  Loss of αT-catenin alters the hybrid adhering junctions in the heart and leads to dilated cardiomyopathy and ventricular arrhythmia following acute ischemia , 2012, Journal of Cell Science.

[9]  K. Green,et al.  Interactions Between Ankyrin-G, Plakophilin-2, and Connexin43 at the Cardiac Intercalated Disc , 2011, Circulation research.

[10]  J. Saffitz.  The pathobiology of arrhythmogenic cardiomyopathy. , 2011, Annual review of pathology.

[11]  G. Radice,et al.  Cardiac Tissue-Restricted Deletion of Plakoglobin Results in Progressive Cardiomyopathy and Activation of β-Catenin Signaling , 2011, Molecular and Cellular Biology.

[12]  J. Molkentin,et al.  Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. , 2010, Circulation.

[13]  M. Bergmann.  WNT signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development. , 2010, Circulation research.

[14]  W. Rottbauer,et al.  Myozap, a Novel Intercalated Disc Protein, Activates Serum Response Factor–Dependent Signaling and Is Required to Maintain Cardiac Function In Vivo , 2010, Circulation research.

[15]  R. Hauer,et al.  Cardiac cell-cell junctions in health and disease: Electrical versus mechanical coupling. , 2009, Journal of molecular and cellular cardiology.

[16]  H. Musa,et al.  Characterization of the molecular phenotype of two arrhythmogenic right ventricular cardiomyopathy (ARVC)-related plakophilin-2 (PKP2) mutations. , 2008, Heart rhythm.

[17]  C. Dai,et al.  Serum-Induced Phosphorylation of the Serum Response Factor Coactivator MKL1 by the Extracellular Signal-Regulated Kinase 1/2 Pathway Inhibits Its Nuclear Localization , 2008, Molecular and Cellular Biology.

[18]  Da-Zhi Wang,et al.  Loss of mXinalpha, an intercalated disk protein, results in cardiac hypertrophy and cardiomyopathy with conduction defects. , 2007, American journal of physiology. Heart and circulatory physiology.

[19]  M. Bergmann,et al.  Role of β-Catenin in Adult Cardiac Remodeling , 2007 .

[20]  R. Duisters,et al.  Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy , 2007, The Journal of experimental medicine.

[21]  M. Hetman,et al.  Role of Megakaryoblastic Acute Leukemia-1 in ERK1/2-Dependent Stimulation of Serum Response Factor-Driven Transcription by BDNF or Increased Synaptic Activity , 2006, The Journal of Neuroscience.

[22]  R. Liao,et al.  The β-Catenin/T-Cell Factor/Lymphocyte Enhancer Factor Signaling Pathway Is Required for Normal and Stress-Induced Cardiac Hypertrophy , 2006, Molecular and Cellular Biology.

[23]  G. Thiene,et al.  The pathophysiology of myocardial reperfusion: a pathologist’s perspective , 2006, Heart.

[24]  Walter Birchmeier,et al.  Balancing cell adhesion and Wnt signaling, the key role of β-catenin , 2006 .

[25]  Marc A Pfeffer,et al.  Controversies in ventricular remodelling , 2006, The Lancet.

[26]  G. Morley,et al.  Cardiac-Specific Loss of N-Cadherin Leads to Alteration in Connexins With Conduction Slowing and Arrhythmogenesis , 2005, Circulation research.

[27]  Hiroyuki Aburatani,et al.  Phosphatidylinositol 3-Kinase–Akt Pathway Plays a Critical Role in Early Cardiomyogenesis by Regulating Canonical Wnt Signaling , 2005, Circulation research.

[28]  V. Ferrari,et al.  Induced Deletion of the N-Cadherin Gene in the Heart Leads to Dissolution of the Intercalated Disc Structure , 2005, Circulation research.

[29]  J. Molkentin,et al.  Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. , 2004, Biochemical and biophysical research communications.

[30]  E. Hirsch,et al.  Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. , 2004, Cardiovascular research.

[31]  J. Molkentin.  Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. , 2004, Cardiovascular research.

[32]  M. Crackower,et al.  The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. , 2004, Journal of molecular and cellular cardiology.

[33]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[34]  Timothy E Hewett,et al.  Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. , 2003, The Journal of clinical investigation.

[35]  J. Woodgett,et al.  Stabilization of β-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Treisman,et al.  Mutant actins demonstrate a role for unpolymerized actin in control of transcription by serum response factor. , 2002, Molecular biology of the cell.

[37]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[38]  K. Khrapko,et al.  Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. , 2001, American journal of physiology. Heart and circulatory physiology.

[39]  R. Kitsis,et al.  The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice , 2000, The EMBO journal.

[40]  D. Kelsell,et al.  Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. , 2000, Human molecular genetics.

[41]  A. Crosby,et al.  Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease) , 2000, The Lancet.

[42]  P. Kang,et al.  The conserved phosphoinositide 3‐kinase pathway determines heart size in mice , 2000, The EMBO journal.

[43]  J. Cohn,et al.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. , 2000, Journal of the American College of Cardiology.

[44]  R. Kraft,et al.  MAPKAP Kinase 2 Phosphorylates Serum Response Factor in Vitro and in Vivo* , 1999, The Journal of Biological Chemistry.

[45]  G L Johnson,et al.  Organization and regulation of mitogen-activated protein kinase signaling pathways. , 1999, Current opinion in cell biology.

[46]  X. Liu,et al.  N-cadherin/catenin-mediated morphoregulation of somite formation. , 1998, Developmental biology.

[47]  A. Clerk,et al.  Cellular mechanisms of cardiac hypertrophy , 1998, Journal of Molecular Medicine.

[48]  A. Clerk,et al.  "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. , 1998, Circulation research.

[49]  A. Clerk,et al.  Regulation of mitogen-activated protein kinase cascades in the heart. , 1998, Advances in enzyme regulation.

[50]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[51]  R Kemler,et al.  Embryonic heart and skin defects in mice lacking plakoglobin. , 1996, Developmental biology.

[52]  W. Birchmeier,et al.  Targeted mutation of plakoglobin in mice reveals essential functions of desmosomes in the embryonic heart , 1996, The Journal of cell biology.

[53]  L. Larue,et al.  Lack of beta-catenin affects mouse development at gastrulation. , 1995, Development.

[54]  R. Treisman,et al.  The Rho family GTPases RhoA, Racl , and CDC42Hsregulate transcriptional activation by SRF , 1995, Cell.

[55]  K E Muffly,et al.  Structural Remodeling of Cardiac Myocytes in Patients With Ischemic Cardiomyopathy , 1992, Circulation.

[56]  A. Cohen-Solal,et al.  [Ventricular "remodeling" after myocardial infarction]. , 1991, Archives des maladies du coeur et des vaisseaux.

[57]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[58]  M. Pfeffer,et al.  Influence of Chronic Captopril Therapy on the Infarcted Left Ventricle of the Rat , 1985, Circulation research.

[59]  A. Gerdes,et al.  Upregulation of γ-catenin compensates for the loss of β-catenin in adult cardiomyocytes , 2007 .

[60]  E. Ehler,et al.  Dilated cardiomyopathy: a disease of the intercalated disc? , 2003, Trends in cardiovascular medicine.

[61]  K. Linask,et al.  N-cadherin is required for the differentiation and initial myofibrillogenesis of chick cardiomyocytes. , 1998, Cell motility and the cytoskeleton.

[62]  R. Hynes,et al.  Developmental defects in mouse embryos lacking N-cadherin. , 1997, Developmental biology.

[63]  N. Sperelakis,et al.  Intercalated discs of mammalian heart: a review of structure and function. , 1985, Tissue & cell.